Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy

Ben‐Baruch, Adit

doi:10.3389/fimmu.2022.903679

Cited by 26 publications

(8 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This cytokine demonstrated its ability to hinder tumor growth by inflicting damage on the tumor vasculature and directly inducing cancer cell apoptosis. These effects were particularly pronounced in cases where NF-κB and JNK activation were impaired [63][64][65][66]. Furthermore, TNF-α exhibited the potential to enhance the effectiveness of cancer treatment drugs/chemotherapy by promoting increased blood vessel permeability [67].…”

Section: Discussionmentioning

confidence: 99%

Effects of Nanosecond Pulsed Electric Field on Immune Checkpoint Receptors in Melanoma Cells

Sauer,

Szlasa,

Szewczyk

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Checkpoint molecules such as PD-1, LAG-3, and TIM-3 are currently under extensive investigation for their roles in the attenuation of the immune response in cancer. Various methods have been applied to overcome the challenges in this field. This study investigated the effects of nanosecond pulsed electric field (nsPEF) treatment on the expression of immune checkpoint molecules in A375 and C32 melanoma cells. The researchers found that the nsPEF treatment was able to enhance membrane permeabilization and morphological changes in the cell membrane without being cytotoxic. We found that the effects of nsPEFs on melanoma included (1) the transport of vesicles from the inside to the outside of the cells, (2) cell contraction, and (3) the migration of lipids from inside the cells to their peripheries. The treatment increased the expression of PD-1 checkpoint receptors. Furthermore, we also observed potential co-localization or clustering of MHC class II and PD-1 molecules on the cell surface and the secretion of cytokines such as TNF-α and IL-6. These findings suggest that nsPEF treatment could be a viable approach to enhance the delivery of therapeutic agents to cancer cells and to modulate the tumor microenvironment to promote an antitumor immune response. Further studies are needed to explore the mechanisms underlying these effects and their impacts on the antitumor immune response, and to investigate the potential of nsPEF treatment in combination with immune checkpoint inhibitors to improve clinical outcomes for cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Nanosecond Pulsed Electric Field on Immune Checkpoint Receptors in Melanoma Cells

Sauer,

Szlasa,

Szewczyk

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…It is also known that AAW tend to have higher systemic inflammation levels and endothelial dysfunction compared with CAW [81]. This can be a consequence of TNF-α overexpression, as well as other pro-inflammatory cytokines secreted by tumor and stromal cells to recruit leukocytes with metastatic effects, to generate cancer stem cells, epithelial-mesenchymal transition (EMT), invasion, resistance to therapy and metabolic reprogramming [82]. Evidence has revealed a pro-tumorigenic role of TNF-α during BC progression and metastasis [83].…”

Section: Bc Immune Landscape and Bc Disparitiesmentioning

confidence: 99%

Biological Basis of Breast Cancer-Related Disparities in Precision Oncology Era

Neagu,

Bruno,

Johnson

et al. 2024

IJMS

View full text Add to dashboard Cite

Precision oncology is based on deep knowledge of the molecular profile of tumors, allowing for more accurate and personalized therapy for specific groups of patients who are different in disease susceptibility as well as treatment response. Thus, onco-breastomics is able to discover novel biomarkers that have been found to have racial and ethnic differences, among other types of disparities such as chronological or biological age-, sex/gender- or environmental-related ones. Usually, evidence suggests that breast cancer (BC) disparities are due to ethnicity, aging rate, socioeconomic position, environmental or chemical exposures, psycho-social stressors, comorbidities, Western lifestyle, poverty and rurality, or organizational and health care system factors or access. The aim of this review was to deepen the understanding of BC-related disparities, mainly from a biomedical perspective, which includes genomic-based differences, disparities in breast tumor biology and developmental biology, differences in breast tumors’ immune and metabolic landscapes, ecological factors involved in these disparities as well as microbiomics- and metagenomics-based disparities in BC. We can conclude that onco-breastomics, in principle, based on genomics, proteomics, epigenomics, hormonomics, metabolomics and exposomics data, is able to characterize the multiple biological processes and molecular pathways involved in BC disparities, clarifying the differences in incidence, mortality and treatment response for different groups of BC patients.

show abstract

“…TNF-α activation improves the mesenchymality of breast cancer stem cells (BCSCs) in triple-negative breast cancer (TNBC), boosting their capacity for invasion, self-renewal, proliferation, and inducing intra-tumoral stromal invasion [ 152 , 153 ]. Additionally, TNF-α stimulates stromal cells to produce matrix metalloprotease (MMP)-2, vascular endothelial growth factor (VEGF)-A, and colony-stimulating factor (CSF)-1, which promotes colon cancer carcinogenesis [ 154 , 155 ]. Another treatment strategy to reduce angiogenic responses in the TME and stop secondary organ metastasis might be to target TNF-α [ 156 , 157 ].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future

Yarahmadi,

Zare,

Aghayari

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Cancer, ranked as the second leading cause of mortality worldwide, leads to the death of approximately seven million people annually, establishing itself as one of the most significant health challenges globally. The discovery and identification of new anti-cancer drugs that kill or inactivate cancer cells without harming normal and healthy cells and reduce adverse effects on the immune system is a potential challenge in medicine and a fundamental goal in Many studies. Therapeutic bacteria and viruses have become a dual-faceted instrument in cancer therapy. They provide a promising avenue for cancer treatment, but at the same time, they also create significant obstacles and complications that contribute to cancer growth and development. This review article explores the role of bacteria and viruses in cancer treatment, examining their potential benefits and drawbacks. By amalgamating established knowledge and perspectives, this review offers an in-depth examination of the present research landscape within this domain and identifies avenues for future investigation. Graphical Abstract The double-edged sword role of bacteria and viruses in cancer therapy.

show abstract

Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy

Cited by 26 publications

References 89 publications

Effects of Nanosecond Pulsed Electric Field on Immune Checkpoint Receptors in Melanoma Cells

Effects of Nanosecond Pulsed Electric Field on Immune Checkpoint Receptors in Melanoma Cells

Biological Basis of Breast Cancer-Related Disparities in Precision Oncology Era

Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future

Contact Info

Product

Resources

About